Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TA-NIC Vaccine for Smoking Cessation
NCT00633321Phase 2Completed
- Sponsor
- Celtic Pharma
- Start
- May 2007
- Primary completion
- Dec 2008
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of TA-NIC in nicotine dependence (3 arms), sponsored by Celtic Pharma. Primary endpoint: 4-week assessment period quit rate at Week 26. Started May 2007; status: completed.
02
Drugs
TA-NIC
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT00633321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00633321.